Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease (LFP-in-PD)

Intracranial Local Field Potential (LFP) Correlates of Neuropsychiatric Symptoms in Parkinson's Disease

This prospective observational cohort study aims to investigate whether intracranial Local Field Potentials (LFPs) recorded from implanted Deep Brain Stimulation (DBS) devices are associated with neuropsychiatric symptoms in people with Parkinson's disease (PD). The study will focus on paroxysmal anxiety, impulse control disorders, and hallucinations.

Twenty participants with Parkinson's disease and an implanted Medtronic Percept DBS device will be recruited. Participants will complete behavioural and clinical assessments and will use the event-marking functionality of the DBS device to record symptom episodes over a monitoring period of approximately 120 days. Brain activity will be passively recorded during this period.

The study will evaluate relationships between LFP signals, symptom occurrence, behavioural task performance, and clinical symptom severity measures. Machine learning approaches will be used to identify electrophysiological patterns associated with neuropsychiatric symptom states at an individual level.

The findings may improve understanding of the neural mechanisms underlying neuropsychiatric symptoms in Parkinson's disease and support the future development of personalised adaptive neuromodulation approaches.

Study Overview

• Status: Not yet recruiting
• Conditions: PARKINSON DISEASE (Disorder)

• Study Type: Observational
• Enrollment (Estimated): 20

Contacts and Locations

• Study Contact: Name: Paul Shotbolt, PhD; Phone Number: +4402078365454; Email: paul.shotbolt@kcl.ac.uk

Study Locations

• China
  • Shanghai, China
    • Ruijin Hospital
    • Contact: Li; Phone Number: 021-64370045; Email: ldy11483@rjh.com.cn
• United Kingdom
  • England
    • London, England, United Kingdom, WC2R 2LS
      • King's College London
      • Contact: Research Governance Office of King's College London; Phone Number: +4402078365454; Email: rgo@kcl.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults with Parkinson's disease and co-occurring neuropsychiatric symptoms, including hallucinations, impulse control disorder, or episodic anxiety, who previously underwent bilateral Deep Brain Stimulation implantation with a Medtronic Percept device as part of routine clinical care at King's College Hospital or affiliated services.

Description

Inclusion Criteria:

• Age ≥ 18 years
• A diagnosis of Parkinson's Disease
• A diagnosis of hallucinations, impulse control disorder, or panic disorder (episodic anxiety)
• Previous bilateral DBS implantation with a Medtronic Percept device as part of clinical care

Exclusion Criteria:

• Non-English speakers
• <18 years old or >75 years old
• A history of concurrent conditions that could significantly confound the study results, such as other significant neurological condition (e.g., brain injury/infection, substance abuse) or concurrent severe psychiatric condition (e.g., schizophrenia)
• Moderate/severe Intellectual Disability or inability to understand study procedures
• Lack of capacity to consent to the study
• Currently involvement in other studies

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Parkinson's Disease Participants With Neuropsychiatric Symptoms and DBS; Participants with Parkinson's disease and co-occurring neuropsychiatric symptoms, including hallucinations, impulse control disorder, or episodic anxiety, who have previously undergone bilateral Deep Brain Stimulation implantation with a Medtronic Percept device as part of clinical care. Participants will undergo clinical and behavioural assessments and longitudinal passive recording of intracranial Local Field Potentials (LFPs) over approximately 120 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease	Association between intracranial Local Field Potential (LFP) recordings from the Medtronic Percept Deep Brain Stimulation device and participant-reported neuropsychiatric symptom events, including hallucinations, impulse control symptoms, and episodic anxiety. Machine learning approaches will be used to identify electrophysiological patterns associated with symptom states.	Baseline through Day 120

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Temporal Dynamics of Neuropsychiatric Symptoms	Characterisation of the frequency, timing, and temporal patterns of participant-reported neuropsychiatric symptom events recorded using the Medtronic Percept device event-marking function.	Baseline through Day 120
Association Between LFP Features and Behavioural Task Performance	Association between Local Field Potential (LFP) features and performance on reward-processing behavioural tasks, including the Monetary Incentive Delay task and Apple Gathering Task.	Baseline assessment at Day 0
Association Between LFP Features and Clinical Symptom Severity Measures	Association between Local Field Potential (LFP) features and validated clinical symptom severity scales, including the Neuropsychiatric Inventory (NPI), Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS), and Parkinson Anxiety Scale (PAS).	Baseline assessment at Day 0

Collaborators and Investigators

• Sponsor: King's College London
• Collaborators: Ruijin Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): February 1, 2028

Study Registration Dates

• First Submitted: May 28, 2026
• First Submitted That Met QC Criteria: June 2, 2026
• First Posted (Actual): June 8, 2026

Study Record Updates

• Last Update Posted (Actual): June 8, 2026
• Last Update Submitted That Met QC Criteria: June 2, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Synucleinopathies; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Parkinson Disease
• Other Study ID Numbers: LFP-in-PD-333102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Individual participant data that underlie the results reported in publications may be shared in anonymised form with qualified researchers upon reasonable request and subject to applicable ethical and institutional approvals. Data sharing will comply with participant consent, data protection regulations, and institutional policies.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No